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Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and 
Blinded Discontinuation After 6 Months 
Research Units on Pediatric Psychopharmacology Autism Network 
Abstract 
Objective: Risperidone is effective for short-term treatment of aggression, temper outbursts, and 
self-injurious behavior in children with autism. Because these behaviors may be chronic, there is a need to 
establish the efficacy and safety of longer-term treatment with this agent. 
Method: The authors conducted a multisite, two-part study of risperidone in children ages 5 to 17 
years with autism accompanied by severe tantrums, aggression, and/or self-injurious behavior who showed 
a positive response in an earlier 8-week trial. Part I consisted of 4-month open-label treatment with 
risperidone, starting at the established optimal dose; part II was an 8-week randomized, double-blind, 
placebo-substitution study of risperidone withdrawal. Primary outcome measures were the Aberrant 
Behavior Checklist irritability subscale and the Clinical Global Impression improvement scale. 
Results: Part I included 63 children. The mean risperidone dose was 1.96 mg/day at entry and 
remained stable over 16 weeks of open treatment. The change on the Aberrant Behavior Checklist 
irritability subscale was small and clinically insignificant. Reasons for discontinuation of part I included 
loss of efficacy (N=5) and adverse effects (N=1). The subjects gained an average of 5.1 kg. Part II included 
32 patients. The relapse rates were 62.5% for gradual placebo substitution and 12.5% for continued 
risperidone; this difference was statistically significant. 
Conclusions: Risperidone showed persistent efficacy and good tolerability for intermediate-length 
treatment of children with autism characterized by tantrums, aggression, and/or self-injurious behavior. 
Discontinuation after 6 months was associated with a rapid return of disruptive and aggressive behavior in 
most subjects. 
Autistic disorder is characterized by impaired social interaction, abnormal language 
development, and repetitive and restricted patterns of behavior (DSM-IV), and it affects as many 
as 20 people per 10,000 (1, 2). Children with autism display broad differences in abilities and 
needs, but accompanying maladaptive behaviors such as self-injurious behavior, aggression, and 
tantrums are common and frequently severe enough to limit educational and developmental 
progress. A variety of treatments, including medication, are employed in the management of 
these maladaptive behaviors. Controlled trials of medication treatment of autism are limited, but 
evidence provides support for both conventional and atypical antipsychotic agents (3, 4). Among 
studies of the conventional antipsychotics, well-controlled trials of haloperidol have revealed 
statistically significant effects, but only modest clinical benefits, in children with autism, and 
short- and longer-term side effects are of concern (3, 5). Atypical antipsychotics appear to be 
preferred by clinicians because of the perception that atypicals have a more favorable side effect 
profile than typical neuroleptics, but few direct comparison data exist. Atypical agents are also of 
interest because of possible serotonin (5-HT) abnormalities in some individuals with autism and 
the high affinity of medicines such as risperidone for 5-HT receptors, especially those of the 
5-HT2A and 5-HT2C classes (6). Until 2002, only one placebo-controlled study of risperidone in 
adults with autism (7) and a handful of open-label studies of children with pervasive 
developmental disorders (8) had been published. In a prior report, we described the short-term 
efficacy of risperidone over placebo in an 8-week controlled trial for 101 children and 
adolescents with autistic disorder (4). Risperidone was chosen for study given the greatest 
preliminary evidence for its efficacy in this population (6, 8). Although the effects of risperidone 
on aggression, tantrums, and self-injurious behavior were substantial in our short-term study, the 
question of whether these improvements would endure over time remained unanswered. 
In this study, subjects who showed a positive response to risperidone in the short-term 
trial were enrolled in an additional 4-month open-label trial (total drug exposure= 6 months), 
which was followed by a placebo-controlled discontinuation protocol lasting up to 8 weeks. The 
aim of the study was threefold: first, to determine if the short-term efficacy of risperidone is 
maintained over time; second, to determine if the side effect burden of risperidone remains 
acceptable over an extended treatment period; and third, to examine the feasibility of risperidone 
discontinuation after 6 months of treatment. 
 
Characteristic Participated in Extension Phase 
(N =63) 
Did Not Participate in 
Extension Phase (N = 38) 
 Mean SD Mean SD 
Demographic profile 
Age (years) 
   
8.6 2.8 9.0 2.5
 Na % Na %
Male sex 49 77.8 33 86.8
Tanner stage I or II 55 87.3 33 86.8
Race or ethnic group    
White 44 69.8 23 60.5
Black 6 9.5 5 13.2
Hispanic 3 4.8 4 10.5
Asian or Pacific Islander 4 6.3 4 10.5
Other (mixed race) 6 9.5 2 5.3
Parental annual income (dollars)b    
≤20,000 6 9.5 7 18.4
20,001–40,000 17 27.0 11 28.9
40,001–60,000 15 23.8 2 5.3
>60,000 23 36.5 18 47.4
Parental education    
Less than high school 1 1.6 2 5.3
High school 13 20.6 6 15.8
Trade or technical school 4 6.3 2 5.3
At least some college 35 55.6 23 60.5
Advanced degree 10 15.9 5 13.2
Living at home with at least one parent 56 88.9 36 94.7
Educational placement    
Regular class 4 6.3 4 10.5
Regular school, special education 47 74.6 27 71.1
Special school 11 17.5 4 10.5
Residential school 0 0.0 1 2.6
Other 1 1.6 2 5.3
Developm
ental 
Profile 
   
IQ 
Above or above 3 4.8 2 5.3
Borderline 7 11.1 5 13.2
Mental retardation    
Mild 17 27.0 8 21.1
Moderate 12 19.0 6 15.8
Severe 11 17.5 7 18.4
Profound 7 11.1 6 15.8
Unable to assess 6 9.5 4 10.5
 Mean SD Mean SD
Scores on Vineland Adaptive Behavior Scales    
Communication 42.6 14.6 44.8 17.0
Socialc 46.4 11.9 51.2 15.7
Daily living 38.5 18.7 35.3 18.6
Maladaptive (part 1) 26.4 5.5 25.2 13.2
Clinical profile    
Scores on Aberrant Behavior Checklist subscales    
Irritability 26.6 7.5 24.6 6.8
Social withdrawal 15.6 7.7 17.4 9.5
Stereotypy 10.2 4.3 9.0 5.2
Hyperactivityd 33.4 8.5 29.7 9.5
Inappropriate speech 6.0 4.0 5.2 3.7
 Na % Na % 
Clinical Global Impression severity score     
4 (moderate) 9 14.3 9 23.7
5 (marked) 36 57.1 19 50.0
6 (severe) 17 27.0 10 26.3
7 (extreme) 1 1.6 0 0.0
Current anticonvulsant treatment 1 1.6 3 7.9
Past treatment profile     
Medication naïve 11 17.7 7 18.4
Antipsychotic 4 6.5 1 2.6
Selective serotonin reuptake inhibitor 9 14.5 7 18.4
Stimulant 16 25.8 5 13.2
Alpha-2 agonist 11 17.7 5 13.2
a The sum of the numbers of subjects may not be the same as the total number because data were missing 
for some variables. 
b Nearly significant difference between groups (χ2=6.94, df=3, p<0.08). 
c Nearly significant difference between groups (t=1.74, df=99, p<0.09). 
d Significant difference between groups (t=2.03, df=99, p<0.05). 
TABLE 1. Baseline Characteristics of Children With Autism Who Responded to Risperidone in an 8-Week 
Trial and Did or Did Not Participate in a 4-Month Open-Label Extension 
Method 
Setting and Subjects 
This study was an extension of the 8-week double-blind, placebo-controlled trial with 
parallel groups and the 8-week open-label risperidone treatment offered to placebo 
nonresponders. These short-term trials were conducted by the Autism Network of the National 
Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology between 
June 1999 and April 2001. The five clinical sites included the University of California at Los 
Angeles, Ohio State University, Indiana University, Yale University, and Kennedy Krieger 
Institute (Johns Hopkins University). The protocol was approved by the institutional review 
board at each site and the NIMH Data and Safety Monitoring Board, and written informed 
consent was obtained from a parent or guardian prior to enrollment. Safety and protocol fidelity 
were monitored through weekly conference calls involving the principal investigators and study 
coordinators, through quarterly reviews by the Data and Safety Monitoring Board, and through 
annual site visits by the coordinating center (Yale University). 
This study enrolled 63 of the 101 subjects in the first protocol, all of whom met criteria 
for autistic disorder as defined in DSM-IV. Other entry criteria (at the time of enrollment in the 
initial double-blind phase) included 1) age of 5–17 years, 2) significant tantrums, aggression, 
self-injurious behavior, and/or agitation, 3) absence of significant medical problems and any 
other psychiatric disorder requiring drug therapy (e.g., bipolar disorder, psychosis), 4) weight of 
at least 15 kg, and 5) mental age of at least 18 months. No concomitant treatment with 
psychotropic medication was allowed during any phase of the study, except anticonvulsant 
treatment for seizure control if the child had been taking a stable dose for 4 weeks and had been 
free of seizures for 6 months (see reference 9 for a detailed description). 
Protocol Schedule and Design 
At the final visit of the initial 8-week controlled study, or the 8-week open-label 
risperidone treatment for placebo nonresponders, subjects deemed responders were offered 
enrollment in the extension protocol. Written informed consent for continued participation was 
obtained from the parents, and for 10 subjects deemed to have the capacity to consent, assent was 
obtained. The subjects were then seen every 4 weeks for 4 months for assessment of efficacy, 
safety, and possible need for dose adjustments. At the end of these 4 months of open-label 
treatment, subjects who continued to show a positive response entered the discontinuation phase. 
In this phase, the subjects were randomly assigned again, this time either to continued 
risperidone at the same dose or to gradual placebo substitution, in a double-blind fashion. The 
discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the 
week 16 dose for 1 week, followed by 50% of the week 16 dose for the second week, 25% of the 
week 16 dose for the third week, and placebo only by the fourth week. All subjects were seen 
weekly for a total of 8 weeks in the discontinuation phase. 
Baseline Assessment and Measurement of Outcome 
At screening for participation in the initial 8-week treatment study, autistic disorder was 
ascertained through a history and examination by a research team and was corroborated by the 
Autism Diagnostic Interview—Revised (10), administered by a clinician trained to reliability 
(11). The screening measures also included intelligence testing, the Vineland Adaptive Behavior 
Scales (12, 13), routine laboratory tests, an electrocardiogram, measurements of height, weight, 
and vital signs, a medical history, and a physical examination. All subjects were also required to 
manifest clinically significant problems consisting of aggression, tantrums, and/or self-injury as 
defined by a score of 18 or higher on the irritability subscale of the Aberrant Behavior 
Checklist—Community version (14, 15) rated by the parent (or primary caretaker) and 
confirmed by clinician review. Scores on this 15-item subscale range from 0 to 45, with higher 
scores indicating greater pathology. In addition, the subjects were required to receive a score of 
moderate or higher on the Clinical Global Impression (GCI) severity scale (16, pp. 218–222) 
from the examining clinician. 
Eligible subjects were randomly assigned to receive risperidone or placebo for 8 weeks; 
details are provided elsewhere (4). The primary outcome measures were the parent-rated 
irritability subscale of the Aberrant Behavior Checklist and the clinician-rated CGI improvement 
scale. Subjects showing a 25% reduction on the irritability subscale and a rating of much 
improved or very much improved on the CGI improvement scale by the blinded clinical 
evaluator were classified as positive responders and were eligible for the 4-month open-label 
extension phase. At the end of the 4-month extension, responders were eligible for the 
randomized discontinuation phase. In the discontinuation phase, relapse was defined as a 25% 
increase in the score on the parent-rated Aberrant Behavior Checklist irritability subscale and a 
CGI improvement rating of much worse or very much worse, compared to the prediscontinuation 
baseline, for at least 2 consecutive weeks, as assessed by a blinded clinician. 
Secondary parent-rated outcome measures included the four additional subscales of the 
Aberrant Behavior Checklist: lethargy/social withdrawal, stereotypic behavior, hyperactivity, 
and inappropriate speech. At baseline, the parents were interviewed to identify the child’s target 
symptoms and to rate compulsive behaviors in the Children’s Yale-Brown Obsessive 
Compulsive Scale (see references 4, 13, and 17 for details on study assessment). 
Medication Dosing 
The medication schedule in the initial 8-week trial was based on the child’s weight and 
clinical response. The maximum risperidone dose was 2.5 mg/day for children between 15 and 
45 kg and 3.5 mg/day for children weighing above 45 kg. Dose reductions to manage side effects 
were allowed at any time. During the 4-month open phase, clinicians were allowed to adjust the 
total daily dose according to response and/or adverse events, with the total daily dose increased 
up to a maximum of 3.5 mg/day for children weighing 15–45 kg and up to 4.5 mg/day for 
children above 45 kg. 
Safety Monitoring 
The routine laboratory tests, electrocardiogram, and physical examination were repeated 
at entry into the extension phase and prior to the discontinuation. Weight and vital signs were 
assessed at each visit. At each visit, the primary clinician asked the parents about the child’s 
health complaints, intercurrent illness, and concomitant medications, and the clinician 
administered a 32-item checklist concerning the child’s energy level, muscle stiffness, motor 
restlessness, bowel and bladder habits, sleep, and appetite. Neurological side effects were further 
assessed at each visit with the Simpson-Angus Rating Scale (18) and the Abnormal Involuntary 
Movements Scale (AIMS) (16, pp. 534–537). Adverse events indicated by any of these methods 
were documented according to severity, duration, attribution, outcome, and action taken. 
 Week 0a  Endpointb Analysis 
(df=1, 58) 
Subscale Mean SD Mean SD F p 
Irritability  9.5 6.8 11.7 8.0 5.35 0.02 
Lethargy/social 
withdrawal 
  
7.3 5.4 6.8 5.9 2.61 n.s. 
Stereotypy 4.9 4.3 5.8 4.7 5.47 0.02 
Hyperactivity 15.1 10.0 15.8 10.2 0.43 n.s. 
Inappropriate 
speech 
3.4 3.6 3.4 3.2 0.39 n.s. 
a Week 0 corresponds to the end of the initial 8 weeks of medication exposure.  
b For patients who discontinued treatment, the last observation was carried forward. 
TABLE 2. Scores on Subscales of the Aberrant Behavior Checklist for 63 Children With Autism Who 
Responded to Risperidone in an 8-Week Trial and Participated in a 4-Month Open-Label Extension 
Statistical Analysis 
Open-label trial. 
The statistical tests were two-tailed with alpha set at 0.05. To evaluate differences 
between subjects who participated in the extension trial and those who did not, we compared 
demographic and clinical characteristics by t tests for continuous variables and chi-square tests 
for categorical variables. All subjects who enrolled in the extension trial were included in an 
intent-to-treat analysis. The monthly scores on the parent-rated subscales (irritability, lethargy, 
stereotypy, hyperactivity, and inappropriate speech) of the Aberrant Behavior Checklist were 
analyzed with mixed effects linear regression models in which time, site, and site-by-time 
interaction were the fixed effects (19). The average slope of the regression line (change in 
irritability score or score on other subscale) was calculated for each individual across time. In 
addition, the distribution of CGI improvement scores was calculated across time. 
Discontinuation phase. 
As originally planned in the protocol, interim analyses were performed for the Data and 
Safety Monitoring Board after the first 16 and 32 subjects completed this phase of the study (9). 
These interim analyses were reviewed only by the Data and Safety Monitoring Board, 
independently of the study investigators. Chi-square analysis with Yates’s correction was used 
to compare the rates of relapse in the two groups. To evaluate the time to relapse and the 
probability of relapse, the log rank survival analysis of continued drug versus placebo and the 
Kaplan-Meier procedure were used. 
Results 
Baseline Characteristics 
Of the original 101 subjects (82 boys and 19 girls) enrolled in the short-term trial, 63 
subjects (mean age=8.6 years, SD=2.8) showed a positive response to risperidone and consented 
to participate in the extension protocol. Of these 63 subjects, 30 were classified as responders 
during the double-blind trial and 30 were so classified in the 8-week open-label risperidone trial 
for placebo non-responders. There were no differences in scores on the irritability subscale of the 
Aberrant Behavior Checklist or in the distribution of CGI severity scores at the baseline of the 
extension phase between subjects who entered directly from the double-blind study and those 
who entered from the 8-week open-label trial for placebo nonresponders. Therefore, the two 
groups were combined in the efficacy analysis. During the data analysis, three subjects were 
noted to have entered the extension phase without fully meeting the response criteria. Inclusion 
of these three subjects did not alter the results, and thus they were included in all analyses. 
Demographic characteristics of the entire 63 subjects in the extension study are shown in Table 
1. When compared to the 38 subjects who did not participate in the extension phase, the 
extension group showed few differences. Of a total of 24 comparisons, only one variable, the 
baseline score on the Aberrant Behavior Checklist hyperactivity subscale, differed significantly, 
being slightly higher at baseline in the subjects continuing in the extension study. 
 
a Week 0 corresponds to the end of the initial 8 weeks of medication exposure. 
b For patients who discontinued treatment, the last observation was carried forward. 
Fig. 1. Scores on the Irritability Subscale of the Aberrant Behavior Checklist for 63 Children With Autism 
Who Responded to Risperidone in an 8-Week Trial and Participated in a 4-Month Open-Label Extension 
4-Month Open-Label Treatment: Outcomes 
A total of 51 subjects (81.0%) completed the 16-week open-label treatment period. Of 
the 12 dropouts from the extension study, five subjects were withdrawn because of loss of 
efficacy, one was withdrawn because of noncompliance with the protocol, one withdrew because 
of an adverse event (constipation), one withdrew consent (no longer interested in medication 
treatment), and four were lost to follow-up. The mixed effects regression model for all 63 
subjects in the intent-to-treat analysis revealed a significant time effect for the irritability 
subscale of the Aberrant Behavior Checklist (Table 2, Figure 1). However, the mean irritability 
ratings showed only a minor increase across the 16-week extension phase, from a mean score of 
9.5 (SD=6.8) at the start to 10.8 (SD=7.1) at week 16 (Figure 1), in contrast to the mean 
pretreatment irritability score of 26.6 (SD=7). 
 
 Week 0a  Week 4 Week 8 Week 12 Week 16 Endpoint 
Rating N % N % N % N % N % N % 
1 (very much improved) 19 30.2 13 20.6 20 33.9 15 26.3 17 33.3 19 30.2 
2 (much improved) 42 66.7 38 60.3 31 52.5 28 49.1 29 56.9 33 52.4 
3 (minimally improved) 0 0.0 7 11.1 5 8.5 11 19.3 2 3.9 6 9.5 
4 (no change) 2 3.2 1 1.6 1 1.7 1 1.8 0 0.0 0 0.0 
5 (worse) 0 0.0 3 4.8 1 1.7 2 3.5 2 3.9 3 4.8 
6 (much worse) 0 0.0 1 1.6 1 1.7 0 0.0 1 2.0 2 3.2 
Total 63 100.0 63 100.0 59 100. 57 100.0 51 100.0 63 100.0 
a Week 0 corresponds to the end of the initial 8 weeks of medication exposure. 
TABLE 3. Clinical Global Impression (CGI) Improvement Ratings for 63 Children With Autism Who 
Responded to Risperidone in an 8-Week Trial and Participated in a 4-Month Open-Label Extension 
This 1-point increase lacks clinical significance. Indeed, after 16 weeks of treatment the 
mean score still showed a 59% reduction from the mean rating at the initiation of risperidone 
treatment 6 months before, a percent reduction identical to that seen after the initial 8-week 
double-blind study and yielding an effect size of d > 1.0. Analysis of the CGI improvement 
ratings at end-point showed that 82.5% of the subjects (N = 52) continued to be rated as much 
improved or very much improved (1 or 2 on the CGI improvement scale) (Table 3). By contrast, 
only 7.9% were rated as worse or much worse compared to baseline. 
The risperidone doses were also examined to determine whether a dose increase is 
required to ensure stability of treatment effects. The mean risperidone doses were 1.96, 1.80, 
1.87, 2.10, and 2.08 mg/day for weeks 0, 4, 8, 12, and 16, respectively, representing a modest 6% 
increase over the 4-month treatment period. 
Secondary outcome measures included the other subscales of the Aberrant Behavior 
Checklist. Table 2 shows scores on those subscales and results of the random regression model. 
4-Month Open-Label Treatment: Adverse Events 
Adverse events, especially mild to moderate increased appetite, tiredness, and/or 
drowsiness, were common (Table 4). Only one subject withdrew because of an adverse event 
(constipation). Although the parents of six subjects (9.5%) reported “abnormal movements,” no 
dyskinesias were identified on repeated examination with the AIMS and Simpson-Angus scale 
by a physician. One subject with preexisting obesity had galactorrhea according to the mother’s 
report, but this was not observed on examination. Compared to their weight at the initiation of 
risperidone treatment, the subjects showed a 6-month weight increase of 5.1 kg (SD=3.6) (paired 
t=7.46, df=31, p<0.001), which was significantly greater (p<0.001) than the amount expected on 
the basis of available developmental norms. This finding has been reviewed in more detail in a 
separate report (20). 
Discontinuation Phase 
A total of 38 subjects were enrolled in the discontinuation phase. Few differences in 
baseline characteristics were observed between the subjects in the discontinuation phase and the 
remainder of the 63 subjects, aside from the discontinuation subjects’ again showing higher 
mean baseline scores on the Aberrant Behavior Checklist hyperactivity factor (mean=34.4, 
SD=8.7, versus mean= 30.6, SD=9.0; t=2.08, df=99, p=0.04). Also, subjects in the 
discontinuation phase showed higher mean baseline scores on the Aberrant Behavior Checklist 
irritability factor than the remaining 63 subjects (mean=27.6, SD=6.1, versus mean 24.8, 
SD=7.7, t=2.02, df=99, p=0.05). As planned, the NIMH Data and Safety Monitoring Board 
independently reviewed two interim efficacy analyses, first after the initial 16 subjects 
completed this phase and again after the first 32 subjects finished. The relapse rate after 32 
subjects completed this phase was significantly higher in the placebo-treated group (62.5%, 
N=10) than in the group receiving continued risperidone (12.5%, N=2) (Yates’s corrected 
χ2=6.53, df=1, p=0.01). The median survival time, i.e., time to relapse, was 34 days for the 
placebo-treated subjects versus 57 days for those continuing to take risperidone (Figure 2). On 
the basis of the results of this planned interim analysis, the NIMH Data and Safety Monitoring 
Board ruled that the discontinuation phase be stopped immediately. The four subjects who were 
still in this phase of the protocol exited the study and were treated clinically. Exploratory post 
hoc analyses were performed in an effort to identify any clinical predictors of relapse. Age, 
initial Aberrant Behavior Checklist irritability score, and IQ all failed to differ significantly 
(p>0.30) between the relapsing and nonrelapsing subjects. 
Discussion 
Data from this study suggest that risperidone is a well-tolerated and effective treatment 
for up to 6 months for children with autism complicated by tantrums, aggression, and self-injury. 
As measured by the primary indices of response, the CGI improvement scale and the Aberrant 
Behavior Checklist irritability subscale, improvements associated with risperidone 
administration were maintained in over 80% of the subjects, with very good tolerability. 
Furthermore, gradual substitution of placebo for risperidone was associated with a greater return 
of aggression, temper outbursts, and self-injurious behavior than in the subjects who continued to 
receive risperidone in the discontinuation phase. Taken together, these data strongly suggest that 
risperidone is an efficacious treatment for short- and intermediate-term management of serious 
behavioral problems in children with autism. 
As in our study of short-term risperidone efficacy (4), risperidone was also associated 
with continued maintenance of improvements on the Aberrant Behavior Checklist subscales for 
hyperactivity, stereotypic behavior, and lethargy/social withdrawal. In addition, the mean 
reduction from baseline in the irritability subscale scores of 59% at the last observation in the 
extension phase was nearly identical to that observed in the risperidone group at the completion 
of the 8-week double-blind efficacy trial. 
 
Adverse Event During 4-Month 
Extensiona 
Number of Subjects With 
Moderate or Severe Event 
Percent of 
Subjects With 
Moderate or 
Severe Event 
Subjects With Events Related to 
Study Drug 
Moderate Severe N % 
Nasal congestion 7 0 11.1 0 0.0 
Appetite increase 5 0 7.9 4 6.3 
Coughing 4 0 6.3 0 0.0 
Anxiety 3 0 4.8 0 0.0 
Difficulty falling asleep 3 0 4.8 0 0.0 
Fever 3 0 4.8 0 0.0 
Skin irritation 3 0 4.8 0 0.0 
Vomiting 3 0 4.8 1 1.6 
Accidental injury 2 0 3.2 0 0.0 
Constipation 2 0 3.2 1 1.6 
Drowsiness/sedation 1 1 3.2 1 1.6 
Enuresis 2 0 3.2 0 0.0 
Headache 2 0 3.2 0 0.0 
Hypersalivation 2 0 3.2 1 1.6 
Sore throat 2 0 3.2 0 0.0 
Depression 0 1 1.6 1 1.6 
Diarrhea 1 0 1.6 0 0.0 
Difficulty urinating 1 0 1.6 0 0.0 
Dyskinesia 1 0 1.6 1 1.6 
Earache 1 0 1.6 0 0.0 
Restlessness/agitation 1 0 1.6 1 1.6 
Sinus condition 1 0 1.6 0 0.0 
Stomach/abdominal discomfort 1 0 1.6 0 0.0 
Tiredness/fatigue 1 0 1.6 0 0.0 
Tremor 1 0 1.6 1 1.6 
Weight gain 1 0 1.6 1 1.6 
Muscle rigidity 1 0 1.6 0 0.0 
Other 1 0 1.6 0 0.0 
a Mild events are not reported. The most severe event is reported if the child reported the event more than 
once. One subject reportedly experienced galactorrhea (see text). 
TABLE 4. Adverse Events in 63 Children With Autism Who Responded to Risperidone in an 8-Week Trial 
and Participated in a 4-Month Open-Label Extension 
As in our study of short-term risperidone efficacy (4), risperidone was also associated 
with continued maintenance of improvements on the Aberrant Behavior Checklist subscales for 
hyperactivity, stereotypic behavior, and lethargy/social withdrawal. In addition, the mean 
reduction from baseline in the irritability subscale scores of 59% at the last observation in the 
extension phase was nearly identical to that observed in the risperidone group at the completion 
of the 8-week double-blind efficacy trial. 
These data expand the limited published database on extended treatment of autistic 
disorder with medication. Heretofore, the largest extended study of neuroleptic treatment for 
autistic disorder was the examination of the effects of haloperidol over a 6-month period. In that 
study (5), 60 children treated with a mean dose of 1.23 mg/day of haloperidol were classified as 
“good responders.” After 6 months of treatment, 33 (63%) of 52 subjects were rated as “much 
improved.” Autism factor ratings derived from the Children’s Psychiatric Rating Scale obtained 
on entry and at 6 months showed an average decline of 23% from baseline. Upon abrupt 
withdrawal of haloperidol, only 14% of the children were rated as much worse and 50% showed 
at least mild deterioration. 
In an open-label prospective study of risperidone for 11 children with autistic disorder, 
Zuddas et al. (21) noted that 10 of the 11 showed enduring improvement over the 12-month 
observation period. Another open trial (22) of risperidone enrolled 22 subjects with autistic 
disorder. Of these, 15 subjects showed significant improvement at a mean dose of 1.2 mg/day for 
up to 7 months of treatment. Additional published observations include positive responses 
maintained over a 4-month period in responders (23) and improvement maintained during a 
2-year treatment history in two adults with autistic disorder (24). It should be noted that few 
earlier studies defined specific entry criteria for aggression or disruptive behavior, but, taken 
together, the available accounts suggest that risperidone’s benefit for aggression, severe 
tantrums, and self-injury accompanying autistic disorder persisted over these intermediate 
treatment periods (6–12 months), although additional long-term treatment data focusing on 
managing severe and challenging behaviors are clearly needed. 
A key clinical question concerns the length of continued treatment with risperidone for 
this clinical indication. On one hand, the return of aggression, tantrums, and agitation was five 
times as great in the placebo-substitution group as in the subjects who continued to take 
risperidone. On the other hand, 37.5% (six of 16) of the children in the placebo-substitution 
group did not relapse during the 2-month discontinuation period, demonstrating some degree of 
variability in outcome. It is conceivable that more gradual drug tapering may have moderated the 
observed relapse in the risperidone group or that dose reduction, rather than complete medication 
discontinuation, may have been sufficient to maintain treatment gains. It is also conceivable that 
concomitant behavioral treatment reinforcing replacement behaviors could protect against 
relapse following risperidone withdrawal. Nevertheless, the high rate of relapse observed in our 
study suggests caution when withdrawal of effective treatment for these target symptoms is 
considered. At a minimum, clinicians should document a clear period of stable functioning 
before initiating medication taper (25) and ensure that appropriate psychosocial supports are in 
place to minimize relapse risk. No factors predicting relapse were identifiable given the modest 
number of subjects in the discontinuation phase of this study, but they certainly form an 
important future research question. Longer-term follow-up information on outcome may help 
clinicians make decisions about maintenance treatment. To this end, we are in the process of 
obtaining 18-month safety data for our study group. 
Although adverse events associated with risperidone exposure were observed to be 
common in this study, most were not deemed clinically significant, and many were not attributed 
to risperidone. It is important that only one subject withdrew from the 4-month open-label 
treatment because of an adverse event, and no cases of dyskinesia were observed during 6 
months of treatment or upon withdrawal. The absence of dyskinesia in this study is noteworthy 
given the report by Campbell and colleagues (26) that 30% of 118 subjects showed dyskinesia 
following withdrawal of haloperidol after a similar duration of treatment, although the more 
gradual taper used in this study may be responsible for the finding. Weight gain associated with 
treatment was significant and in some, but not all, cases posed a concern (20), especially since 
antipsychotic-related weight gain has been associated with diabetes and other adverse outcomes. 
Longer-term observations to determine the clinical significance of weight gain as well as other 
adverse events are needed to evaluate the risk-benefit ratio for risperidone treatment in children 
with autistic disorder. 
There were several limitations in this investigation. First, although the data collection 
period in this phase of the study spanned up to a maximum total of 8 months of risperidone 
exposure, this does not completely mimic clinical practice, as many patients receive treatments 
like risperidone for longer time periods. Also, there was no systematic effort to reduce or 
constrain individual daily doses over time, leaving some uncertainty about the lowest possible 
long-term dose. This limitation notwithstanding, the relatively low mean dose (approximately 2.0 
mg/day) of risperidone used in this study was effective in managing the specific target symptoms 
of aggression, agitation, and self-injury. This mean dose was remarkably similar to the doses in 
several other studies (16, 22, 27, 28). The possibility of solidifying these gains or even extending 
the benefit of risperidone treatment by combining it with behavior therapy was not explored in 
this investigation but is an important research question for future studies. Finally, the safety 
observations of the study were limited to a maximum of 8 months of risperidone exposure in a 
relatively small study group. Thus, our data may be insufficient to estimate precisely the 
long-term risks of risperidone in children. 
 
Fig. 2. Survival Analysis for Children With Autism Who Responded to Risperidone and Were Then 
Randomly Assigned to Placebo or Continued Risperidone for 8 Weeksa 
a For the placebo group, the risperidone dose was decreased by 25% per week. Relapse was defined as a 25% 
increase in the score on the Aberrant Behavior Checklist irritability subscale and a CGI improvement rating of 
much worse or very much worse, compared to the prediscontinuation baseline, for at least 2 consecutive 
weeks. The difference between groups was significant (test for equality of survival distributions for 
treatment, log rank=6.89, df=1, p=0.009). 
In summary, intermediate-length treatment with risperidone appeared to be associated 
with the maintenance of reductions in aggression, agitation, self-injury, and irritability from 
short-term treatment. There was little evidence of accommodation to the effects of risperidone, 
and the medication appeared to be well tolerated in a group of children and adolescents with 
autistic disorder. Additional studies on predictors of stable improvement, longer-term safety, and 
approaches combining other interventions are of interest. 
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